Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Payables (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Payables for 2 consecutive years, with $10.9 million as the latest value for Q4 2025.

  • Quarterly Payables rose 124.02% to $10.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.9 million through Dec 2025, up 124.02% year-over-year, with the annual reading at $10.9 million for FY2025, 124.02% up from the prior year.
  • Payables for Q4 2025 was $10.9 million at Pyxis Oncology, up from $9.8 million in the prior quarter.
  • The five-year high for Payables was $10.9 million in Q4 2025, with the low at $2.3 million in Q1 2024.